Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. (NYSE: BAX) today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies (PI). The company also introduced HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], as the submitted brand name for the investigational product, previously referred to as HyQ. Posters and oral presentations regarding the HyQvia clinical program will be given during the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual meeting in Orlando.

"The HyQvia clinical program has been focused on obtaining long-term data about this new facilitated subcutaneous immunoglobulin therapy, including safety, efficacy, tolerability, and pharmacokinetic data," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business. "This information may be used to inform physicians in making the most appropriate treatment choice for their patients."

Selected study data of interest:

  • Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (Melamed, Oral session 4602-764, Monday, March 5, 2:00 pm)

  • Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (Stein, Poster session 2203-55, Monday, March 5, 9:45 am)

  • Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (Wasserman, Poster session 2203-56, Saturday, March 3, 9:45 am)
Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 20). Long-term data from Baxter's HyQ clinical study on PI. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20120303/Long-term-data-from-Baxters-HyQ-clinical-study-on-PI.aspx.

  • MLA

    Baxter International Inc.. "Long-term data from Baxter's HyQ clinical study on PI". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20120303/Long-term-data-from-Baxters-HyQ-clinical-study-on-PI.aspx>.

  • Chicago

    Baxter International Inc.. "Long-term data from Baxter's HyQ clinical study on PI". News-Medical. https://www.news-medical.net/news/20120303/Long-term-data-from-Baxters-HyQ-clinical-study-on-PI.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2019. Long-term data from Baxter's HyQ clinical study on PI. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20120303/Long-term-data-from-Baxters-HyQ-clinical-study-on-PI.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients